XARELTO® Cases Consolidated In Louisiana Before Judge Fallon
On Friday, December 12, 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated that Xarelto personal injury lawsuits against Johnson & Johnson’s entity Janssen Pharmaceuticals, Inc. and Bayer Corp. Various plaintiffs claim that the blood-thinning medication Xarelto carried insufficient warning labels that failed to adequately notify patients about the risks of uncontrollable bleeding.
The JPML consolidates lawsuits when there are common factual questions in a multitude of lawsuits to warrant centralization of the cases. This means that one judge in Louisiana will preside over a large number of cases filed in or removed to federal court. The judge selected is Judge Eldon E. Fallon of the U.S. District Court for the Eastern District of Louisiana.
For those unfamiliar with this process, the purpose of consolidating the cases is to streamline pretrial proceedings and avoid the duplication of discovery by joining similar cases into one action. The process is meant to promote judicial efficiency, economy, and fairness. This is not a class action; each cases is still filed individually unlike in a class action, where there is one representative plaintiff for all members of the class. Multi-district litigations are normally formed in pharmaceutical lawsuits and have been an effective manner in resolution.
Claudine Q. Homolash, Esquire, founder of the CQH Firm, is a whistleblower, pharmaceutical injury and personal injury lawyer representing clients nationwide. She can be contacted at email@example.com or (844) 677-4276 or (215) 496-1012 for a free legal consultation.